The slide to be stained for
MLH1 comprised:
1. Appendix, 2. Tonsil, 3. Colon adenocarcinoma with loss of MLH1
expression, 4. Colon adenocarcinoma with normal MLH1 expression.
All tissues were fixed in 10% neutral buffered formalin.
Criteria for assessing a MLH1 staining as optimal included:
- An at least weak to moderate nuclear
staining reaction of almost all cells in the appendix.
- An at least weak to moderate nuclear
staining reaction in the mantle zone B-cells and a moderate to
strong nuclear staining reaction in the germinal centre B-cells.
- A moderate to strong nuclear staining in
the neoplastic cells of the colon adenocarcinoma no. 4.
- A negative staining reaction in the
neoplastic cells of the colon adenocarcinoma no. 3, and a
distinct nuclear reaction in all other cells.
- A weak cytoplasmic reaction was accepted.
85 laboratories participated in this
assessment. 57 % achieved a sufficient mark. In table 1 the
antibodies (Abs) used and marks are summarized.
Table 1.
Abs and
assessment marks
for MLH1, run 30
|
Concentrated Abs |
N |
Vendor |
Optimal |
Good |
Borderl. |
Poor |
Suff.1 |
Suff. OPS2 |
|
mAb clone
G168-15 |
33
8
1 |
BD Pharmingen
Biocare
Zytomed |
10 |
11 |
15 |
6 |
50 % |
70 % |
|
mAb clone
ES05 |
16
3 |
Novocastra/Leica
Dako |
11 |
5 |
2 |
1 |
84 % |
100 % |
|
mAb clone
G168-728 |
1 |
BD Pharmingen |
0 |
0 |
0 |
1 |
- |
- |
|
Ready-To-Use Abs |
|
|
|
|
|
|
|
|
|
mAb clone
ES05, IR079 |
7 |
Dako |
7 |
0 |
0 |
0 |
100 % |
100 % |
|
mAb clone
ES05, PA0610 |
1 |
Leica |
1 |
0 |
0 |
0 |
- |
- |
|
mAb clone
G168-728, 760-4264 |
11 |
Ventana |
0 |
2 |
7 |
2 |
18 % |
- |
|
mAb, clone
G168-728, 285M & CMA869 |
3 |
Cell Marque |
1 |
0 |
2 |
0 |
- |
- |
|
mAb, clone
G168-15 PM220 |
1 |
Biocare |
0 |
1 |
0 |
0 |
- |
- |
|
Total |
85 |
|
30 |
19 |
26 |
10 |
- |
- |
|
Proportion |
- |
|
35 % |
22 % |
31 % |
12 % |
57 % |
- |
1) Proportion of sufficient stains
(optimal or good), 2) Proportion of sufficient stains with optimal
protocol settings only, see below.
Following central protocol parameters were used to obtain an optimal
staining:
Concentrated Abs
mAb clone G168-15: The protocols giving an optimal result
were all based on heat induced epitope retrieval (HIER) using either
Tris-EDTA/EGTA pH 9 (3/13)*, TRS pH 9 (Dako) (2/8), TRS pH 9
(3-in-1, Dako) (1/3), Bond Epitope Retrieval Solution 2 (Bond,
Leica) (3/8) or EDTA/EGTA pH 8 (1/1) as the retrieval buffer. The
mAb was typically diluted in the range of 1:25– 1:50 depending on
the total sensitivity of the protocol employed. Using these protocol
settings 16 out of 23 (70 %) laboratories produced a sufficient
staining (optimal or good).
* (number of optimal results/number of laboratories using this
buffer).
mAb clone ES05: The protocols giving an optimal result were
all based on HIER using either Tris-EDTA/EGTA pH 9 (3/3), TRS pH 9 (Dako)
(2/2), TRS pH 9 (3-in-1, Dako) (3/3), Bond Epitope Retrieval
Solution 1 (Bond, Leica) (1/1) or Bond Epitope Retrieval Solution 2
(Bond, Leica) (2/2) as the retrieval buffer. The mAb was typically
diluted in the range of 1:25-1:100 depending on the total
sensitivity of the protocol employed. Using these protocol settings 11 out of 11 (100 %) laboratories produced an
optimal staining.
Ready-To-Use Abs
mAb clone ES05 (prod. no. IR079, Dako): The protocols giving
an optimal result were all based on HIER in PT-Link using TRS pH 9
or TRS pH 9 (3-in-1) and an incubation time of 20 min in the primary
Ab and EnVision Flex (K8000) or Flex+ (K8002) as the detection
system. Using these protocol settings all of 7 (100 %)
laboratories produced an optimal staining.
mAb clone ES05 (prod. no. PA0610, Leica): The protocol giving
an optimal result was based on HIER using Bond Epitope Retrieval
Solution 2 (Bond, Leica) and an incubation time of 15 min in the
primary Ab and Bond Polymer Refine Detection (DS9800) as the
detection system.
mAb clone G168-728 (prod. no. CMA869, Cell Marque): The
protocol giving an optimal result was based on HIER using Bond
Epitope Retrieval Solution 2 (Bond, Leica) and an incubation time of
16 min in the primary Ab and Bond Polymer Refine Detection (DS9800)
as the detection system.
- - -
The most frequent causes of insufficient staining reactions were:
- Less successful Ready-To-Use (RTU) mAb clone G168-728 (Ventana, 11/15
insufficient)
- Use of low sensitive detection systems
- Too low concentration of the primary Ab
- HIER in a non-alkaline buffer
In this assessment and in concordance to the previous NordiQC
assessment for MLH1, run 13, 2005, the prevalent feature of an
insufficient staining was a too weak or false negative staining of
the majority of the cells expected to be demonstrated. The majority
of the laboratories were able to demonstrate MLH1 in the cells with
a high antigen expression as the proliferating germinal centre
B-cells and the basal epithelial cells of the appendix, whereas the
demonstration of MLH1 in cells with a low antigen expression as
mantle zone B-cells, smooth muscle cells and stromal cells could
only be obtained by an optimally calibrated protocol. In this context
it has to be emphasized, that the identification of loss of MLH1 in
tumours is characterized by a negative immunoreaction of the
neoplastic cells wherefore it is of decisive importance that the
nonneoplastic cells within and around the tumour are stained, serving as
internal positive control.
An efficient HIER in an alkaline buffer such as
Tris-EDTA/EGTA pH 9, BERS2 (Leica) or TRS pH 9 (Dako) - irrespective
of the mAb clone applied - seemed mandatory to obtain an optimal
staining. If combined with the use of a 3-step polymer based
system (e.g., EnVision Flex+, Dako, or Refine, Leica) a very robust
protocol was achieved. With HIER in an alkaline buffer
and a 3-step polymer system, 33 out of 37 laboratories (89
%) obtained a sufficient result, of which 25 (67 %) were optimal.
Using HIER in an alkaline buffer and a less sensitive 2-step polymer
or multimer based system (e.g. EnVision Flex, Dako or UltraView,
Ventana) only 12 out of 38 (32 %) obtained a sufficient result, of
which 5 (13 %) were optimal.
In this assessment the newly launched mAb clone ES05 from
Novocastra/Leica and Dako obtained a very high pass rate both as a
concentrate (84 %)
and in the RTU format (100 %).
The mAb clone G168-728 was less successful especially in the RTU
format from Ventana and Cell Marque, where only 4 out of 15
laboratories (27 %) using this product obtained a sufficient result,
of which only 1 was assessed as optimal. The optimal result was
obtained using the Bond III, Leica and HIER in BER2 and a 3-step
polymer based system, Refine Leica.
A significant difference in the overall performance for MLH1 was
also related to the IHC platform applied. Only 6 out of 25 (24 %)
protocols performed on the fully automated platform BenchMark XT or
Ultra, Ventana were assessed as sufficient, none were optimal. In
contrast, 10 out of 13 (77 %) protocols performed on a
similar fully automated platform Bond-max or Bond III were assessed
as sufficient, out of which 8 (62 %) were optimal.
Tonsil is a recommendable positive control for MLH1: The
mantle zone B-cells must show at least a weak to moderate nuclear
staining, while a moderate to strong staining must be seen in the
proliferating germinal centre B-cells.
This was the 2nd assessment of MLH1 in NordiQC. The proportion of sufficient results
decreased from 72 % in run 13, 2005, to 57 % in the current run
(Table 2). The
lower pass rate may be due to several factors (new tissue material
circulated, many new participants).
Table 2:
Proportion of sufficient results for MLH1 in the two NordiQC runs
performed
| |
Run 13
2005 |
Run 30 2010 |
|
Participants, n= |
25 |
85 |
|
Sufficient results |
72 % |
57 % |
Conclusion
The mAb clones G168-15 and ES05 can both be used to obtain an
optimal staining for MLH1. In this assessment the mAb clone ES05 was
most successful, both as concentrate and in an RTU format.
HIER in alkaline buffer and the use of a 3-step polymer based detection
system gave the most robust protocol. Tonsil is a recommendable
positive control for MLH1: The mantle zone B-cells must show
at least a weak to moderate nuclear staining, while a moderate to
strong staining must be seen in the proliferating germinal centre
B-cells. |